Rabin Martin’s Post

What's next in 2024 as a health policy and systems researcher in Thailand? Our Value-Based Healthcare Policy Lab is dedicated to strengthening cancer care in the Thai context, engaging multiple stakeholders from both the private and public sectors, including healthcare organizations, policymakers, the pharmaceutical industry, and patients. Our efforts will continue in 2024 to create a higher quality of care for cancer patients in our country. #VBHC #cancercare #healthpolicy #healthsystemsresearch

Join me in a few weeks to learn how biopharmas big and small can get treatments to patients faster than ever with #VeevaCompass: https://bit.ly/3SqPG4k

The 5R Framework at AstraZeneca's outcomes up to 2018 highlights: -improved R&D productivity >4 fold (from 4% to 19%) -Doubled hit to lead success rate from 23% to 48% -Cycle times reduced by 7 months -Focus on quality over quantity 2005-2010: 297 projects initiated ~28% back-ups 2012-2016: 76 projects initiated ~7% back-ups -Greater focus on disease and target validation -Expanding drug target classes to follow disease biology -New projects more likely to use phenotypic screens -Kinases have become the predominant target class (from 21% to 36%), driven by an emphasis on oncology, and the proportion of projects targeting G protein-coupled receptors has declined (from 25% to 5%) and ion channels (from 8% to 2%) Paywall link to review: https://lnkd.in/eY9UVtbZ AstraZeneca's blog on transforming R&D productivity: https://lnkd.in/eU6gKfZu Would be great to hear an update on this from Executive Vice President Prof Sir Mene Pangalos and team before he retires in March 2024: https://lnkd.in/enEGDB_5

Today, I had the pleasure of participating in an engaging discussion on Statistical Design Considerations in Estimating the Contribution of Each Sequential Treatment Effect to the Overall Effect of a Sequence of Treatments in Randomized Cancer Clinical Trials. Organized by the American Statistical Association Biopharmaceutical Section’s Statistical Methods in Oncology Scientific Working Group and the LUNGevity Foundation, in collaboration with the Oncology Center of Excellence at the US Food and Drug Administration. SMART designs and multi-phase treatment regimens present inherent complexities. Today's forum emphasized the crucial role of collaboration across diverse stakeholders and disciplines in effectively tackling these challenges. It was inspiring to witness insightful contributions from academia, industry, and regulatory bodies! 🌟 #ClinicalTrials #OncologyResearch #Collaboration #Biostatistics #StatisticalDesigns

🌟 Exciting Biotech News! 🌟 Uniquity Bio has been unveiled by Blackstone Life Sciences with a whopping $300 million backing! 💰 This new biotech is set to make waves in the field of inflammation and immunology. Their lead asset, Solrikitug, an anti-TSLP antibody in-licensed from Merck & Co., has just received FDA approval for two phase 2 studies in chronic obstructive pulmonary disease (COPD) and asthma. 🚀 Nicholas Galakatos, Ph.D., head of life science investments at Blackstone, shared, "We are proud to partner with Uniquity’s team of veteran industry leaders as they advance solrikitug and expand their immunology and inflammation pipeline with additional programs in the near future." With the immunology and inflammation market expected to grow by more than 150% by 2032, Uniquity Bio is positioned to stand out in a competitive space. They aim to challenge established players like AstraZeneca and Amgen with their "highly potent" TSLP receptor binder. Uniquity's launch is part of a series of significant private financing rounds in the I&I sector. Just last week, Attovia Therapeutics launched with $105 million, Zenas BioPharma secured $200 million in series C capital, and Mirador Therapeutics entered the scene with $400 million. Now, Uniquity joins this exciting trend with the full support of Blackstone. Kiran Reddy, M.D., Senior Managing Director at Blackstone, added, “We’re excited about the work that Uniquity has done so far with solrikitug and look forward to providing long-term financial support to the company.” #Biotech #Immunology #Inflammation #Blackstone #UniquityBio #HealthcareInnovation #Pharma #Investment #COPD #Asthma #TSLP #DrugDevelopment

🎉 Wishing everyone a Prosperous New Year in 2024! 🌟🥳 As we embark on this new journey, we are excited to highlight the significant achievements Okomera attained in 2023 and our ambitious agenda for 2024. 🚀 2023 - A Year of Go-to-Market Kickstart: 🌍 Successfully implemented our product across three key quarters worldwide: Paris, France; Cambridge, UK; and the San Francisco Bay Area, United States. 🤝 Initiated our groundbreaking commercial partnership with a major pharmaceutical leader. 💰 A triumphant seed funding round equipped us with the necessary resources to expedite our market penetration. 2024 - A Year of Growth: 🔬 We're broadening our early adopters program to extend support to additional pharmaceutical firms, facilitating accelerated drug discovery. 🏥 Our strategic plan includes installations in renowned cancer centers across Europe and the United States, strengthening cancer research and data generation. A special salute to CRCM - Centre de Recherche en Cancérologie de Marseille, our upcoming clinical collaborator—we're eager to join forces with you! 🎁 Our dedicated efforts focus on streamlining and enhancing our product to meet high-throughput and automation demands, introducing new features for seamless integration into your organoid analysis workflow. Stay tuned for further updates—2024 holds exciting opportunities, and we're eager to unite in the fight against cancer! 🤝🧪

🧭📅🔬 𝟮𝟬𝟮𝟰 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝗲𝘀 𝘂𝗽𝗱𝗮𝘁𝗲 𝗮𝘁 𝗮𝗻𝗻𝘂𝗮𝗹 𝗝.𝗣. 𝗠𝗼𝗿𝗴𝗮𝗻 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 🔬📅🧭 At the #JPM2024 Healthcare Conference, our CEO and co-founder Ugur Sahin will provide an update later today on our objectives for 2024 and beyond. In 2024, we aim to advance additional product candidates in oncology into the later stages of clinical development and plan to have 10 or more potentially registrational trials by the end of 2024 while we expect to maintain global COVID-19 vaccine market leadership together with our collaborator Pfizer. In parallel, we at BioNTech are scaling our commercial infrastructure for #oncology, including specialized commercial teams in North America, Europe and other major markets with the aim to be commercially ready by the end of 2025. We expect to grow our #topline again in 2025. In the outer years, we project revenues to derive from both oncology and respiratory combination vaccine launches, which are subject to successful development and regulatory approval. We remain focused on the development of the next wave of medical innovations in various fields and indications while we continue to be cost disciplined. We are as optimistic as ever about our ability to continue to create long-term value for patients, our key stake- and shareholders as well as society. Read more: https://lnkd.in/dyUieafx

Meet the visionary guiding transformative innovation: Ms. Rose Satz, CEO and Co-Founder of AIP (Advanced Innovative Partners). AIP pioneers patented technologies targeting complex conditions in oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures. Precision medicine is their hallmark, honing in on cancers while protecting healthy cells. Beyond science, AIP stands poised for impact. Regulatory approvals span drug phases, inviting compelling investments in the radiopharmaceutical boom. At the core is Ms. Rose Satz, a seasoned businesswoman with international business and marketing management degrees. Her networking prowess shines as she forges connections. As CEO of AIP, she embodies entrepreneurship, pioneering uncharted paths. Ms. Satz's journey extends beyond. She advised Johnson & Johnson and shaped international pharma. Her network bridges scientific leaders, research giants, and manufacturing partners, fueling diagnostics and therapeutics. This synergy between Ms. Satz and AIP propels transformative solutions at the intersection of science and innovation. Discover her insights, motivations, and aspirations in our revealing PharmaFEATURES interview. https://lnkd.in/gfdnqpiw #oncology #cancer #raredisease #rarepediatricdiseases #infection #infectiousdiseases #biomedicalwarfare #bioweaponry #biohazard #precisionmedicine

Check out this week's Healthcare Report where we discuss news surrounding hims & hers and AstraZeneca! Hims & Hers’ announcement boosted its stock, reflecting investor optimism about the new offering. AstraZeneca's expansion in Singapore aligns with its global strategy to enhance production capabilities. This move is crucial for AstraZeneca's growth and commitment to improving oncology patient outcomes. Also, comment your email address to be a part of our mailing list! Analyst: Pakhi Sahni

DaSH-Global and Clinical Net were delighted to attend ESMO23 - where Andrew Turner and Nuria Coll Bastus caught up with friends, colleagues & clients to announce our new collaboration to accelerate drug development and approval while empowering cancer patients to take more control over their care. The coalition offers an end-to-end, cost- and time-saving approach to bring new treatments to people faster. The companies will synergise patient-centred digital healthcare tools to boost patient recruitment in clinical trials and generate hand-by-hand real-world data to expedite clinical research and reimbursement of new medicines. #patientcentricity #patientoutcomes #patientexperience #proms #qualityoflife #heor #medicalaffairs #marketaccess #regulatoryaffairs #lungcancerawareness #lungcancer #mesothelioma #ai #bigdata #oncology #healthcare #pharmaceutical #data #machinelearning  #digital #clinicaltrials Vivienne Law Dominic Cameron Sanjoy Paul, Ph.D., M.Sc. Alfonso Aguarón Kai Stoeber Iftekhar Kalsekar Bryan Bennett Hazel Jacobs  Robin Munro Alan Calleja Gavin Bell, CFA David Walters James McDonald Qing Huang Sarah Fleming, PhD Nikhil Tanna Ana Maria Cravo, PhD Nuria Coll Bastus Lee Wemyss Lee Holmes Catherine F. William Dolben Simon Thorn